Pembrolizumab plus enfortumab vedotin in urothelial cancer

Affiliations

• ¹ Oncology Unit, Macerata Hospital, Macerata, Italy.
• ² Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
• ³ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. [email protected].
• ⁴ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. [email protected].
• ⁵ 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
• ⁶ Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.
• ⁷ Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
• ⁸ Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
• ⁹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
• ¹⁰ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
• ¹¹ Medical Oncology Unit, University Hospital of Parma - Department of Medicin and Surgery, University of Parma, Parma, Italy.
• ¹² Department of Molecular Medicine, Sapienza University, Rome Italian Pasteur Institute, Cenci-Bolognetti Foundation, Rome, Italy.
• ¹³ Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.